Despite poor retail sales stocks bounced higher for the fourth straight session. Energy and Biotech stocks led the overall market today. Energy seems to be finding support at early 2015 lows. Biotech continues its run despite fundamentalists crying foul over earnings multiples. Transportation stocks lagged the market along with utilities. Bonds rallied a bit today as they continue to remain […]
Stocks rebounded in typical fashion Wednesday, with most sectors participating equally. Trading levels picked up as these days are becoming very obvious to the masses. The smart money is looking for the bounce that fails – signifying a change in market behavior. Recent bounces haven’t lead to much – with only modest gains being achieved all year. Leading stocks moved […]
Stocks moved lower on Tuesday, extending the pullback from recent highs. Trading picked up as money appears to be shifting out of index names. Leading stocks generally dropped, but not the usual 2x pace of the market. In fact, there were plenty of leaders that moved higher or held strong. Biotechs were flashing buy signals (OTIC, ZFGN, etc.) or were […]
Stocks put in a modest rally Thursday, lead again by biotechs and high quality growth names. Trading volume was light, however, indicating a modest shift – not a mad rush. This is very evident in the intraday action – or lack thereof. This shift into quality names – however slow it may be – is becoming persistent. It isn’t providing […]
By Ben LevisohnYes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos(RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:
October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years. We believe […]
[at Seeking Alpha] – Faheem Hasnain Thanks, Graham. There are three major topics that we’re going to cover on the call today. First, with regard to RPC1063 in relapsing MS, I want to remind you where we stand with the program … moreView todays social media effects on RCPTView the latest stocks trending across Twitter. Click to view dashboardSee who […]
moreView todays social media effects on RCPTView the latest stocks trending across Twitter. Click to view dashboardSee who Receptos is hiring next, click here to view […]
moreView todays social media effects on RCPTView the latest stocks trending across Twitter. Click to view dashboardSee who Receptos is hiring next, click here to view […]
[GlobeNewswire] – – Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 – – Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally – – Results … moreView todays social media effects on RCPTView the latest stocks trending across Twitter. Click to view dashboardSee who Receptos is hiring next, click here […]
moreView todays social media effects on RCPTView the latest stocks trending across Twitter. Click to view dashboardSee who Receptos is hiring next, click here to view […]
